Prévisions

Acheter	5
Conserver	1
Vendre	0

Actualités Accéder au fil d'actualités

Takeda refocuses on upcoming launches after pipeline investments

Takeda outlines a two-stage strategy emphasizing heavy pipeline investment and imminent launches (Horizon One), followed by a growth phase (Horizon Two). ORZEYFUL, the orexin agonist for narcolepsy type 1, received FDA approval and is awaiting DEA scheduling ahead of a planned US launch later this year. The selective TYK2 inhibitor zasocitinib has a PDUFA date of 13 March 2027 and is cited with peak sales potential of $3–6 billion for psoriasis/psoriatic arthritis; additional data on inflammatory bowel disease are expected by the end of fiscal 2024. R&D chief Andy Plump is retiring, Julie Kim is expected to shape future strategy; a more detailed update is scheduled for the capital markets day on 11 December in Tokyo. » Plus sur de.investing.com
Takeda: FDA accepts application for psoriasis drug Zasocitinib for priority review

The FDA has accepted Takeda’s New Drug Application for Zasocitinib (TAK-279) to treat moderate-to-severe plaque psoriasis for priority review; the PDUFA target date is Q1 2027. The EMA has also accepted the marketing application. The submission is supported by two phase III trials in which around 70% of patients achieved nearly clear skin after 16 weeks; key endpoints were met and no new safety signals emerged. Takeda does not expect the submission to have a material impact on consolidated financial guidance for the fiscal year ending 31 March 2027. » Plus sur de.investing.com
Takeda receives FDA approval for blood cancer drug Mimrylo

The FDA has approved Mimrylo (active ingredient rusfertid) from Takeda for the treatment of erythrocytosis in adults with polycythaemia vera. The decision is based on the phase‑III VERIFY study with 293 patients, in which 76.9% of treated patients showed a clinical response between weeks 20 and 32 and reduced hematocrit levels, fewer phlebotomies, and relief of fatigue were documented. Mimrylo is administered once weekly subcutaneously; common adverse events were injection‑site reactions (56%) and anemia (16%). Takeda holds the exclusive global development and commercialization rights and does not expect an impact on consolidated guidance for the fiscal year. » Plus sur de.investing.com

Dividendes historiques Dividendes

Tous les indicateurs de dividendes Tous les indicateurs

En 2026, Takeda Pharmaceutical a déjà versé 0,54 € de dividendes. Le dernier versement a eu lieu en juin.

Données financières de l'entreprise

Au dernier trimestre, Takeda Pharmaceutical a réalisé un chiffre d'affaires de 6,57 Md € et un bénéfice net de 609,83 M €

(EUR)	juin 2026	YoY
Chiffre d'affaires	6,57 Md	0,66 %
Bénéfice brut	4,38 Md	25,79 %
Bénéfice net	609,83 M	16,80 %
EBITDA	1,82 Md	29,95 %

Données fondamentales

Indicateur	Valeur
Capitalisation boursière	52,47 Md €
Nombre d'actions	1,59 Md
Plus haut/bas sur 52 semaines	33,75 € - 22,95 €
Rendement du dividende	3,34 %
Dividendes TTM	1,10 €
Bêta	0,10
Ratio P/E	51,60
Ratio PEG	1,68
Ratio P/B	1,22
Ratio P/S	2,03

Profil de l'entreprise

Takeda Pharmaceutical Company Limited beschäftigt sich mit der Erforschung, Entwicklung, Herstellung, Vermarktung und Auslizenzierung von pharmazeutischen Produkten weltweit. Das Unternehmen bietet pharmazeutische Produkte in den Bereichen Gastroenterologie, Onkologie, Neurowissenschaften und seltene Krankheiten wie seltene Stoffwechselkrankheiten, Hämatologie und vererbbare Angioödeme sowie aus Plasma gewonnene Therapien und Impfstoffe an. Das Unternehmen bietet seine Produkte unter den Marken Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro und Alunbrig an. Takeda Pharmaceutical Company hat Lizenzvereinbarungen mit Denali Therapeutics und Wave Life Sciences Ltd; Kooperationsvereinbarungen mit Neurocrine Biosciences, Inc. und Rani Therapeutics LLC; Lizenz- und Forschungsvereinbarungen mit The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc. und Arrowhead Pharmaceuticals Inc.; Forschungskooperationsvereinbarungen mit Arrowhead Pharmaceuticals Inc. und Ovid Therapeutics Inc. sowie eine Kooperation mit Evox Therapeutics Ltd. und eine Lizenzvereinbarung mit ProThera Biologics Inc. Außerdem unterhält das Unternehmen strategische Allianzen mit Egle Therapeutics SAS, Evotec SE, Neurocrine Biosciences, Inc. und Carmine Therapeutics, HemoShear Therapeutics, LLC, KSQ Therapeutics und Anima Biotech. Die Takeda Pharmaceutical Company Limited wurde 1781 gegründet und hat ihren Hauptsitz in Tokio, Japan.

Nom	Takeda Pharmaceutical
PDG	Julie So-Young Kim
Siège social	Tokyo, os Japon
Site web	takeda.com
Secteur	Santé
Industrie	Produits pharmaceutiques
Introduction en bourse	04/01/2000
Employés	47 029